sameAs
P185
A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical TrialsCommon variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcomaPhase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors.The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study.Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoformReovirus: Rationale and clinical trial update.Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines.Chromatin Regulators as a Guide for Cancer Treatment ChoiceClinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?The potential of exploiting DNA-repair defects for optimizing lung cancer treatment.Targeting FGFR Signaling in Cancer.Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies.Rationale for anti-OX40 cancer immunotherapy.Immune-related adverse events with immune checkpoint blockade: a comprehensive review.Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials.Mutational Landscape and Sensitivity to Immune Checkpoint Blockers.Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape.Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system.A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer.Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials.Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.Patients aged over 75 years enrolled in Phase I clinical trials: the Gustave Roussy experience.Modifying phase I methodology to facilitate enrolment of molecularly selected patients.Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early TrialsClinical benefit of early phase clinical trial participation for advanced sarcoma patients.First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours.In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.Tumour markers fluctuations in patients with medullary thyroid carcinoma receiving long-term RET inhibitor therapy: ordinary lapping or alarming waves foreshadowing disease progression?Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).
P50
Q28551817-A695C027-6A22-4559-BF66-2769390FCD17Q29028729-33DBCC6A-F6E7-4260-BF32-470E098C451CQ33167870-80B1A50C-4E72-4A57-AD78-468087C54369Q34059707-1BEDE340-47F2-4407-99DA-E474A38C7B0CQ34139534-94E7A944-DA0C-4BD0-A96C-E89816C96BB1Q34987379-1DBA2BFC-0E56-4CD4-B3CF-FB4971B5D656Q35006739-02FB89A4-C764-42B9-A076-686265B96166Q36713548-12C6CE59-7D80-4600-B18A-CF0513C38ED3Q37075234-7DA90D4B-D369-431D-8266-5606BE4D0E80Q37222606-76B28C94-D6E8-4C5D-8297-00F6C869AE85Q37644608-A90A68C2-217A-4D0D-BC88-6CCC95F47129Q37983690-E3B1DF84-9A10-4B63-8DD1-BE6D0C37EEF2Q38528810-6EEF7BC4-805E-4850-8EDB-CE807DAC8EC2Q38616101-59673685-E53A-4CEC-8469-FFD007B1EA4AQ38636711-5BC02D2C-42F9-41AD-9DFB-ED294CE84048Q38662311-0DA9240A-8D77-4936-A2A1-206C9E5054C7Q38696141-2FF02B44-3C5F-47C7-B48A-471A37D830FEQ38735014-8D60BEEB-CB63-4EE5-9F3B-F5643E113E63Q38889870-6524FF5A-E053-4ECB-B1C4-700332178FAFQ38922208-489DC14E-C3B8-44BE-BB21-64495EB79A5AQ38948345-1451CB51-1576-4F1F-A958-7EAA942FEDEFQ39112227-DD791FD7-0821-46E1-A48E-B962352E8EFAQ39846121-7DF20A10-D5D9-4288-B40E-D15A4E7BE1D8Q40482977-5374613F-28F6-408D-AE15-858EA85E09A1Q40539792-52403522-EEC1-4A35-B37A-FD42DD0877A6Q43803879-91A0E131-2217-4FD2-B786-F5F58551C6D9Q45274026-476808B2-0597-4C38-8A25-51C8F397ABAFQ46177233-9F0B07C8-6B0B-4B7C-9CAC-E0A8AB2EC089Q47343253-17B3BE6D-5097-43EF-810B-AA9E84154EC2Q47416333-388D119B-F150-49E3-9F9C-BE68B94AA04DQ47599265-B3F76DC4-8F38-4FB0-A1AB-6FD48293467BQ47678135-8EA3AF20-EA74-4685-AC0A-79A7994D92B4Q47927037-FCAB3F0E-AC7F-4A83-9041-BB5BD3AB0619
P50
description
French MD
@en
Médecin-chercheur française
@fr
onderzoeker
@nl
name
Sophie Postel-Vinay
@ast
Sophie Postel-Vinay
@en
Sophie Postel-Vinay
@es
Sophie Postel-Vinay
@fr
Sophie Postel-Vinay
@sl
type
label
Sophie Postel-Vinay
@ast
Sophie Postel-Vinay
@en
Sophie Postel-Vinay
@es
Sophie Postel-Vinay
@fr
Sophie Postel-Vinay
@sl
prefLabel
Sophie Postel-Vinay
@ast
Sophie Postel-Vinay
@en
Sophie Postel-Vinay
@es
Sophie Postel-Vinay
@fr
Sophie Postel-Vinay
@sl
P214
P244
P268
P269
P4285
P106
P184
P2038
Sophie_Postel-Vinay
P21
P213
0000 0003 7022 6198
P214
P244
n2013180883
P268
P269
P27
P31
P4285
P569
1950-01-01T00:00:00Z
P734
P735
P7859
lccn-n2013180883